NCT05442346View on ClinicalTrials.gov

Safety and Efficacy Evaluation of γ-globin Reactivated Autologous Hematopoietic Stem Cells

NASuspendedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

December 25, 2023

Primary Completion Date

September 8, 2024

Study Completion Date

November 30, 2024

Conditions
Thalassemia Major
Interventions
BIOLOGICAL

γ-globin reactivated autologous hematopoietic stem cells

gene edited autologous hematopoietic stem cells with γ-globin expression; BRL-103

Trial Locations (1)

200241

Shanghai Bioray Laboratories Inc, Shanghai

Sponsors
All Listed Sponsors
collaborator

First Affiliated Hospital of Guangxi Medical University

OTHER

lead

Bioray Laboratories

INDUSTRY

NCT05442346 - Safety and Efficacy Evaluation of γ-globin Reactivated Autologous Hematopoietic Stem Cells | Biotech Hunter | Biotech Hunter